Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2007 2
2008 7
2009 12
2010 5
2011 3
2012 4
2013 3
2014 2
2015 2
2016 1
2019 1
2020 2
2021 1
2022 3
2024 3
2025 9
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry.
Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Torri V, Hejleh TA, Takada K, Naqash AR, Garassino M, … See abstract for full author list ➔ Cortellini A, et al. Among authors: karapanagiotou e. J Immunother Cancer. 2025 Feb 4;13(2):e010674. doi: 10.1136/jitc-2024-010674. J Immunother Cancer. 2025. PMID: 39904562 Free PMC article.
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry.
Cortellini A, Santo V, Brunetti L, Garbo E, Pinato DJ, La Cava G, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Alessi JV, Montrone M, Owen DH, Ramella S, Signorelli D, Fidler MJ, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D'Alessio A, Banna GL, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Nana FA, Dingemans AM, Aerts JGJV, Ferrara R, Abu Hejleh T, Takada K, Naqash AR, … See abstract for full author list ➔ Cortellini A, et al. Among authors: karapanagiotou e. J Immunother Cancer. 2025 Sep 29;13(9):e012423. doi: 10.1136/jitc-2025-012423. J Immunother Cancer. 2025. PMID: 41022528 Free PMC article.
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity.
Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato DJ, Naidoo J, Loza M, Genova C, Gettinger S, Kim SY, Jayakrishnan R, Zarif TE, Russano M, Pecci F, Di Federico A, Montrone M, Owen DH, Signorelli D, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Yendamuri S, Grossi F, Josephides E, Tomasik B, Giusti R, Bria E, Sebastian M, Rost M, Acker F, Landi L, Mazzoni F, Morabito A, Leonetti A, Cantini L, Mountzios G, Kalvapudi S, O'Reilly D, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Piedra A, Cortinovis DL, Tonini G, Minuti G, Mezquita L, Gorria T, Beninato T, Lo Russo G, PrelaJ A, De Giglio A, Biello F, Nana FA, Dingemans AC, Aerts JG, Ferrara R, Abu Hejleh T, Takada K, Naqash AR, Garassino MC, Wakelee HA, Nassar A, Ricciuti B, Soda P, Caruso CM, Guarrasi V. Cortellini A, et al. Among authors: karapanagiotou e. Lung Cancer. 2025 Nov;209:108799. doi: 10.1016/j.lungcan.2025.108799. Epub 2025 Oct 16. Lung Cancer. 2025. PMID: 41108882 Free article.
Bevacizumab-induced hypertension: pathogenesis and management.
Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Syrigos KN, et al. Among authors: karapanagiotou e. BioDrugs. 2011 Jun 1;25(3):159-69. doi: 10.2165/11590180-000000000-00000. BioDrugs. 2011. PMID: 21627340 Review.
Predictors and Outcomes of Non-Small Cell Lung Carcinoma Patients Following Severe Immune Checkpoint Inhibitor Toxicity: A Real-World UK Multi-Centre Study.
Mahmood U, Josephides E, Chitnis M, Skwarski M, Gennatas S, Ghosh S, Spicer J, Karapanagiotou E, Ahmad T, Forster M, Jamal-Hanjani M, Benafif S, Swanton C, Lee SM, Papadatos-Pastos D, Georgiou A, Coupe N. Mahmood U, et al. Among authors: karapanagiotou e. Cancers (Basel). 2025 Aug 28;17(17):2819. doi: 10.3390/cancers17172819. Cancers (Basel). 2025. PMID: 40940918 Free PMC article.
A Propensity-Matched Comparison Between Minimally Invasive Surgery and Stereotactic Radiotherapy in the Treatment of Clinical Stage IA Non-Small-Cell Lung Cancer (NSCLC).
Josephides E, Daddi N, Bertoglio P, Lugaresi M, Patel A, Farinelli E, Fabbri G, Volpi S, Frezza G, Routledge T, Ahmad S, Van Hemelrijck M, Karapanagiotou E, Smith D, Piergiorgio S, Billè A. Josephides E, et al. Among authors: karapanagiotou e. Clin Lung Cancer. 2025 Sep;26(6):e399-e408.e2. doi: 10.1016/j.cllc.2025.04.011. Epub 2025 Apr 29. Clin Lung Cancer. 2025. PMID: 40410021 Free article.
Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies.
Patel A, Wakeam E, Josephides E, Lampridis S, Karapanagiotou E, Middleton G, Naidu B, De Perrot M, Bille A. Patel A, et al. Among authors: karapanagiotou e. J Immunother Cancer. 2026 Feb 4;14(2):e014098. doi: 10.1136/jitc-2025-014098. J Immunother Cancer. 2026. PMID: 41638870 Free PMC article. Review.
PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer.
Hughes DJ, Chand G, Johnson J, Tegala R, Bailey D, Adamson K, Edmonds S, Meszaros LK, Moore AEB, Manickavasagar T, Ndagire S, Gennatas S, Georgiou A, Ghosh S, Josephs D, Karapanagiotou E, McLean E, Ting HH, Spicer J, Goh V, Cook GJR. Hughes DJ, et al. Among authors: karapanagiotou e. Br J Cancer. 2025 Jun;132(10):913-921. doi: 10.1038/s41416-025-02991-w. Epub 2025 Apr 5. Br J Cancer. 2025. PMID: 40188291 Free PMC article. Clinical Trial.
58 results